Capital Lp Commodore Net Worth

The estimated Net Worth of Capital Lp Commodore is at least $4.04 million dollars as of 7 August 2023. Capital Commodore owns over 775,756 units of Satsuma Pharmaceuticals stock worth over $1,732,500 and over the last 3 years Capital sold STSA stock worth over $2,307,500.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Commodore STSA stock SEC Form 4 insiders trading

Capital has made over 14 trades of the Satsuma Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently Capital bought 775,756 units of STSA stock worth $17,958,751 on 7 August 2023.

The largest trade Capital's ever made was selling 3,250,000 units of Satsuma Pharmaceuticals stock on 14 November 2022 worth over $2,307,500. On average, Capital trades about 304,003 units every 44 days since 2021. As of 7 August 2023 Capital still owns at least 1,575,000 units of Satsuma Pharmaceuticals stock.

You can see the complete history of Capital Commodore stock trades at the bottom of the page.

What's Capital Commodore's mailing address?

Capital's mailing address filed with the SEC is 444 MADISON AVENUE, 35TH FLOOR, NEW YORK, NY, 10022.

Insiders trading at Satsuma Pharmaceuticals

Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... et Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Complete history of Capital Commodore stock trades at Vistagen Therapeutics, Imara Inc et Satsuma Pharmaceuticals

Satsuma Pharmaceuticals executives and stock owners

Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Kollins,
  President, Chief Executive Officer, Director
• Tom O'Neil,
  Chief Financial Officer
• Detlef Albrecht,
  Chief Medical Officer
• John A. Kollins,
  Pres, CEO & Director
• Dr. Detlef F. Albrecht,
  Chief Medical Officer
• Thomas P. O'Neil,
  Chief Financial Officer
• Thomas King,
  Independent Director
• Michael Riebe,
  Independent Director
• Elisabeth Sandoval,
  Independent Director
• Ken Takanashi,
  Independent Director
• Rajeev Shah,
  Independent Director
• Thomas Soloway,
  Director
• Rob Janosky,
  Chief Commercial Officer
• Mic Iwashima,
  Vice President & Head of Operations
• Heath Lukatch,
  Independent Chairman of the Board
• Alan C. Mendelson J.D.,
  Sec.
• Robert M. Janosky,
  Chief Commercial Officer
• Dr. Shannon Strom Ph.D.,
  VP & Head of Regulatory Affairs
• Robert Schultz,
  VP & Head of CMC
• Mic Iwashima,
  VP & Head of Operations
• Capital Lp Commodore,
  10% owner
• Capital Management, L.P.Ra ...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Thomas P. O'neil,
  Chief Financial Officer
• Capital Management, L.P.Ra ...,
  
• Mutya Harsch,
  Director
• Braden Michael Leonard,
  10% owner
• Nippon Biomedical Laborator...,
  10% owner